Creatine for amyotrophic lateral sclerosis/motor neuron disease

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 12, 2012, Pages

  Pastula, Daniel M ^a   Moore, Dan H ^b   Bedlack, Richard S ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; NEUROPROTECTIVE AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; DISEASE COURSE; DRUG EFFECT; HUMAN; META ANALYSIS; MORTALITY; MOTOR NEURON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VITAL CAPACITY;

AMYOTROPHIC LATERAL SCLEROSIS; CREATINE; DISEASE PROGRESSION; HUMANS; MOTOR NEURON DISEASE; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAL CAPACITY;

EID: 84874136165     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005225.pub3     Document Type: Article

References (44)

1. Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Annals of Neurology 2003;53(4):437-45. [PUBMED: 12666111]
2. Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, et al. Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotrophic Lateral Sclerosis 2008;9(5):266-72. [PUBMED: 18608103]
3. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al. NEALS Consortium. A clinical trial of creatine in ALS. Neurology 2004;63(9):1656-61. [PUBMED: 15534251]
4. Rosenfeld J. Creatine monohydrate in amyotrophic lateral sclerosis: preliminary results. American Academy of Neurology Annual Meeting. 2001.
5. Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Medicine 2008;10(4):275-90.
6. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. New England Journal of Medicine 1994;330(9):585-91.
7. Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annual Review of Biochemistry 1985;54:831-62.
8. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2000;1(5):293-9.
9. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). Journal of the Neurological Sciences 1999;169(1-2):13-21.
10. Chancellor AM, Slattery JM, Fraser H, Swingler RJ, Holloway SM, Warlow CP. The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. Journal of Neurology 1993;240(6):339-46.
11. Cox D. Regression models and life tables. Journal of the Royal Statistical Society. Series B (Methodological) 1972;34(2):187-220.
12. Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. Journal of Neurology 2006;253(11):1428-36.
13. Del Aguila M, Longstreth WT Jr, McGuire V, Koepsell T, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60(5):813-9.
14. Drory VE, Gross D. No effect of creatine on respiratory distress in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2002;3(1):43-6.
15. Goodall EF, Morrison KE. Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Reviews in Molecular Medicine 2006;8(11):1-22.
16. Gordon PH, Miller RG, Moore DH. ALSFRS-R. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2004;5(Suppl 1):90-3.
17. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
18. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
19. Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T. Bipap improves survival and rate of pulmonary function decline in patients with ALS. Journal of the Neurological Sciences 1999;164(1):82-8.
20. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine 1999;5(3):347-50.
21. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group II. Neurology 1996;47(6 (Suppl 4)):S242-50.
22. Lawler JM, Barnes WS, Wu G, Song W, Demaree S. Direct antioxidant properties of creatine. Biochemical & Biophysical Research Communications 2002;290(1):47-52.
23. Li TM, Alberman E, Swash M. Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease. Journal of Neurology, Neurosurgery & Psychiatry 1988;51(6):778-84.
24. Mandrioli J, Faglioni P, Merelli E, Sola P. The epidemiology of ALS in Modena, Italy. Neurology 2003;60(4):683-9.
25. Mathus-Vliegen LMH, Louwerse LS, Merkus MP, Tytgat GNS, Vianney de Jong JMP. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointestinal Endoscopy 1994;40(4):463-9.
26. Mazzini L, Corrà T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. Neurology 1995;242(10):695-8.
27. Mazzini L, Balzarini C, Colombo R, Moro G, Pastore I, De Ambrogio R, et al. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. Journal of the Neurological Sciences 2001;191(1-2):139-44.
28. Meyer RA, Sweeney HL, Kushmerick MJ. A simple analysis of the "phosphocreatine shuttle". American Journal of Physiology 1984;246(5 Pt 1):C365-77.
29. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73(15):1218-26.
30. Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology 2005;25(3):114-9.
31. Pastula DM, Coffman CJ, Allen KD, Oddone EZ, Kasarskis EJ, Lindquist JH, et al. Factors associated with survival in the National Registry of Veterans with ALS. Amyotrophic Lateral Sclerosis 2009;10(5-6):332-8.
32. Przedborski S, Mitsumoto H, Rowland LP. Recent advances in amyotrophic lateral sclerosis research. Current Neurology and Neuroscience Reports 2003;3(1):70-7.
33. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362(6415):59-62.
34. Rowland LP, Schneider NA. Amyotrophic lateral sclerosis. New England Journal of Medicine 2001;344(22):1688-700.
35. Sanofi-Aventis. Rilutek prescribing information. Sanofi-Aventis U.S.LLC, Bridgewater, NJ November 2006.
36. Sestili P, Martinelli C, Bravi G, Piccoli G, Battistelli M, Falcieri E, et al. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radical Biology and Medicine 2006;40(5):837-49.
37. Siddique T, Hentati A. Familial amyotrophic lateral sclerosis. Clinical Neuroscience 1995-1996;3(6):338-47.
38. Sorenson EJ, Stalker AP, Kurland LT, Winderbank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002;59(2):280-2.
39. Testa D, Lovati R, Ferrarini M, Salmoiraghi F, Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2004;5(4):208-12.
40. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study 1996-2000. Journal of Neurology, Neurosurgery and Psychiatry 2003;74(9):1258-61.
41. Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME, NEALS Consortium. Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004;63(10):1933-5.
42. Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. Journal of the Neurological Sciences 2001;191(1-2):3-9.
43. Bedlack RS, Mathew MC. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD005225]
44. Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD005225.pub2]